Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Search trials by disease or condition

Enter a condition, keyword, or NCT ID

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “breast cancer”

Partial Breast Irradiation Without Sentinel Lymph Node Biopsy in Low-Risk Early Breast CancerNot Yet Recruiting
NCT07757958Phase 3Updated Aug 11, 2026
Sponsor: Samsung Medical Center
Breast Cancer · Node-negative Breast Cancer · Early-Stage Invasive Breast Carcinoma
South Korea
A Comparative Study of Delayed Endoscopic DTI and Latissimus Dorsi ±Impalnt Reconstruction Post-MastectomyNot Yet Recruiting
NCT07757074N/AUpdated Aug 11, 2026
Sponsor: Du Zhenggui
Breast Cancer
China
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast CancerActive Not Recruiting
NCT05113251Phase 3Updated Aug 11, 2026
Sponsor: AstraZeneca
Breast Neoplasms · Breast Cancer · HER2-positive Early Breast Cancer
United States, Brazil, Bulgaria, Canada, China +13 more
Comprehensive Lifestyle Change To Prevent Breast CancerActive Not Recruiting
NCT03448003NAUpdated Aug 11, 2026
Sponsor: M.D. Anderson Cancer Center
Premenopausal
United States
Slow Jogging for Breast Cancer SurvivorsRecruiting
NCT07757763NAUpdated Aug 11, 2026
Sponsor: Mackay Memorial Hospital
Breast Neoplasms
Taiwan
A Study of MGC026 in Participants With Advanced Solid TumorsRecruiting
NCT06242470Phase 1Updated Aug 11, 2026
Sponsor: MacroGenics
Advanced Solid Tumor · Advanced Cancer · Metastatic Cancer · Squamous Cell Carcinoma of Head and Neck
United States, Australia, United Kingdom
A Trial of HRS-6209-205 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Combination Therapy in Subjects With HR-Positive/HER2-Negative CancerRecruiting
NCT07358377Phase 1Updated Aug 11, 2026
Sponsor: Atridia Pty Ltd.
Breast Cancer
Australia
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)Active Not Recruiting
NCT06680921Phase 3Updated Aug 11, 2026
Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
Locally Advanced or Metastatic Breast Cancer
China
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast CancerRecruiting
NCT07405801Phase 2Updated Aug 11, 2026
Sponsor: Hoffmann-La Roche
Breast Cancer
United States, Argentina, Brazil, Canada, France +7 more
Gonadotropin-Releasing Hormone Agonists Benefit in Preserving the Ovarian Function in Premenopausal Breast Cancer Patients During ChemotherapyCompleted
NCT07127315NAUpdated Aug 11, 2026
Sponsor: Helwan University
Gonadotropin Releasing Hormone Agonists · Ovarian Function · Premenopausal · Breast Cancer
Egypt
Establishment and Clinical Transformation of ADC Drug Efficacy Evaluation System for Breast Cancer Based on Molecular ImagingRecruiting
NCT06715020NAUpdated Aug 11, 2026
Sponsor: Peking University Cancer Hospital & Institute
Breast Cancer
China
A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast CancerNot Yet Recruiting
NCT07757230Phase 2Updated Aug 11, 2026
Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.
Metastatic Breast Cancer
China
Preventing High Blood Sugar in People Being Treated for Metastatic Breast CancerActive Not Recruiting
NCT05090358Phase 2Updated Aug 11, 2026
Sponsor: Memorial Sloan Kettering Cancer Center
Breast Cancer · Breast Cancer Stage IV · Metastatic Breast Cancer
United States
Mammography, Early Detection Biomarkers, Risk Assessment, and Imaging Technologies, MERIT StudyRecruiting
NCT03408353N/AUpdated Aug 11, 2026
Sponsor: M.D. Anderson Cancer Center
Breast Carcinoma
United States
A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast CancerRecruiting
NCT07347600N/AUpdated Aug 11, 2026
Sponsor: Hoffmann-La Roche
Locally Advanced Breast Cancer · Metastatic Breast Cancer
China
A Prospective Multicenter Study of the TuFEst-LN Model for Axillary Lymph Node Status Assessment in Breast CancerRecruiting
NCT07304934N/AUpdated Aug 10, 2026
Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
Breast Cancer · Axillary Lymph Node Metastasis
China
SMC Radiation Oncology Breast Cancer Cohort StudyActive Not Recruiting
NCT05775757N/AUpdated Aug 10, 2026
Sponsor: Samsung Medical Center
Radiotherapy Side Effect
South Korea
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)Recruiting
NCT06926868Phase 2, Phase 3Updated Aug 10, 2026
Sponsor: Bristol-Myers Squibb
Breast Neoplasms
United States, Argentina, Australia, Austria, Brazil +23 more
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast CancerRecruiting
NCT07100106Phase 1, Phase 2Updated Aug 10, 2026
Sponsor: Genentech, Inc.
Breast Cancer
United States, Australia, Brazil, Canada, China +5 more
Effect of a Mushroom Extract-Containing Topical Cosmetic Formulation During Breast RadiotherapyCompleted
NCT07755553NAUpdated Aug 10, 2026
Sponsor: Hifas da Terra S.L.
Radiation Dermatitis · Breast Cancer
Spain
Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV InfectionRecruiting
NCT07383649Phase 2Updated Aug 10, 2026
Sponsor: The Methodist Hospital Research Institute
Brain Cancer Metastatic · CMV Viremia
United States
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)Active Not Recruiting
NCT05952557Phase 3Updated Aug 10, 2026
Sponsor: AstraZeneca
Breast Cancer, Early Breast Cancer
United States, Argentina, Australia, Austria, Belgium +39 more
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast CancerRecruiting
NCT05111561Phase 1Updated Aug 10, 2026
Sponsor: National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm · Metastatic Malignant Solid Neoplasm · Refractory Malignant Solid Neoplasm · Triple-Negative Breast Carcinoma
United States
Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Estrogen-Positive Breast Cancer Over Age 65Active Not Recruiting
NCT02564848NAUpdated Aug 10, 2026
Sponsor: Cedars-Sinai Medical Center
Breast Cancer
United States
Connecting Black Families in Houston, Texas to Hereditary Cancer Genetic Counseling, Genetic Testing, and Cascade Testing by Using a Simple Genetic Risk Screening Tool and TelegeneticsRecruiting
NCT05694559NAUpdated Aug 10, 2026
Sponsor: M.D. Anderson Cancer Center
Breast Cancer · Colorectal Cancer
United States

Previous page Next page